GlassScriptPhysician profile
Slade Braswell
NPI 1922512839
$3,757.85
in general payments reported to CMS, 2019-2025
34 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.87 · 2022: $130 · 2023: $1,204 · 2024: $1,209 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.25 | 2023-2025 | |
| Lilly USA, LLC | $415.82 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $410.72 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $244.29 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $205.83 | 2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $195.84 | 2023-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $190.89 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.87 | 2023-2025 | Jardiance |
| Medtronic, INC. | $171.03 | 2025 | Affera Mapping System, Pulseselect |
| Merck Sharp & Dohme LLC | $156.01 | 2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $105.48 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $105.35 | 2025 | Symbravo |
| Abbott Laboratories | $97.03 | 2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $96.46 | 2024-2025 | |
| Hologic Sales and Service, LLC | $93.28 | 2025 | Thinprep 2000 Processor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $75.21 | 2022 | |
| Nevro Corp. | $56.33 | 2024 | Senza |
| Lundbeck LLC | $50.73 | 2024 | Vyepti |
| Corium, LLC | $48.60 | 2024 | Azstarys |
| Corcept Therapeutics | $45.10 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $29.90 | 2024 | |
| Irhythm Technologies, INC. | $23.77 | 2024 | Zio Xt Patch, Zio Monitor |
| Gilead Sciences, INC. | $20.59 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.40 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $16.98 | 2025 | |
| Dexcom, INC. | $16.67 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $15.70 | 2025 | Nuzyra |
| Exact Sciences Corporation | $14.89 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $14.28 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.49 | 2023 | |
| Sumitomo Pharma America, INC. | $13.15 | 2023 | Gemtesa |
| Vivus LLC | $12.81 | 2023 | Qsymia |
| Phathom Pharmaceuticals, INC. | $4.21 | 2025 | Voquezna |
| Genentech USA, INC. | $3.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Slade Braswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.